Signed, Sealed, Delivered:
Evolving Treatment Options for the Management of Perianal Fistula in Crohn’s Disease

Roundtable #2 and Live Q&A
.

Certification period for this program has expired. No credit will be offered beyond the program dates noted on the bottom of this page.

This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and Bonum CE in partnership with MondayNightIBD.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A. Inc.

Program Overview

When perianal fistulas (PAF) develop in Crohn’s disease (CD), poor long-term outcomes in patients with CD can be predicted. There are many identifiable gaps regarding the treatment of PAF in CD, and it is important to update clinicians on the current state of PAF in CD epidemiology, management best practices, and evolving treatment options.

This CME-certified, webinar will begin with an overview of Crohn’s perianal fistulas (CPF), focusing on initial and multidisciplinary management of CPF, management of complex CPF after biologic failure (particularly the use of Mesenchymal stem cells), and conclude with a dedicated portion on the patient perspective.

Faculty

Aline Charabaty, MD, AGAF, FACG
Assistant Clinical Director of the Division of Gastroenterology
Johns Hopkins School of Medicine
Clinical Director of IBD
Johns Hopkins - Sibley Memorial Hospital
Washington, DC

Marla Dubinsky, MD
Professor of Pediatrics and Medicine
Chief, Division of Pediatric Gastroenterology and Nutrition
Co-Director, Susan and Leonard Feinstein IBD Center
Director, Marie and Barry Lipman IBD Preconception and Planning Clinic
Mount Sinai Kravis Children’s Hospital
Icahn School of Medicine Mount Sinai New York
New York, NY

Amy Lightner, MD
Associate Professor of Surgery
Department of Colon and Rectal Surgery
Associate Chair of Surgical Research
Associate Professor of Inflammation and Immunity
Lerner Research Institute
Cleveland Clinic
Cleveland, OH

Brandon Pomish
PF Patient
Board Member,
Crohn’s & Colitis Foundation
Michigan Chapter
Detroit, MI

Target Audience

This program is intended for gastroenterologists, surgeons, pharmacists, nurses, nurse practitioners, physician associates/physician assistants, and internists.

Learning Objectives

After completing this activity series, learners should be better able to:

  • Review current best practices for the management of Crohn’s perianal fistula (CPF)

  • Assess data gaps and the need to establish studies evaluating management of patients with treatment refractory CPF

  • Evaluate current and emerging treatment options for patients with CPF

  • Describe the health burden and psychosocial effects for patients with CPF

Disclosure of Relevant Financial Relationships

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

 

  • Aline Charabaty, MD, AGAF, FACG
    Consultant/Advisor/Speaker: AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, Takeda

    Marla Dubinsky, MD
    Consultant/Advisor/Speaker: AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, Prometheus Biosciences, Takeda

    Amy Lightner, MD
    Consultant/Advisor/Speaker: Mesoblast, Ossium, Takeda, Boomerang Medical; CMO: Direct Biologics

    Brandon Pomish
    Nothing to disclose

  • PACE, Bonum CE staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.

Joint Accreditation Statement

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Bonum CE. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit & Fee Information

In order to receive credit for this activity, the participant must read the front matter, achieve a passing score of 75% on the post-test, complete the evaluation and application for credit form.

There is no fee to participate in this activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirements

All Bonum CE digital activities require the following hardware/software to view and participate:

  • Internet connection (via PC or Mac desktop or laptop computer, tablet, mobile device, etc.)

  • PowerPoint and/or a PDF viewer may be required on some activities

We recommend a minimum of:

  • 128MB RAM

  • Processor speed of 500MHz or higher

  • 800x600 color monitor

  • Video or graphics card

  • Sound card and speakers

To actively participate in Bonum’s social media (SoMe)-based CME programs, learners will need to have an established account in good standing on that hosting SoMe site. Learners will need to be logged-in to the SoMe hosting platform.

For additional information about the accreditation of this activity, please visit https://www.partnersed.com

Release date: January 11, 2023
Expiration date: January 11, 2024
Estimated time to complete activity: 60 minutes